Navigation Links
Crux Biomedical Announces First Successful U.S. Implant of Its New Retrievable Inferior Vena Cava (IVC) Filter
Date:10/3/2007

ATLANTA, Oct. 3 /PRNewswire/ -- Crux Biomedical, Inc., a privately held medical device firm, announced that it has successfully completed the first implant in the United States of the Crux IVC Filter. The filter, used to prevent an often fatal pulmonary embolism (PE), was implanted at the Atlanta Medical Center by David Rosenthal, Chief of Vascular Surgery. Every year in the United States, approximately 600,000 patients develop a PE and between 120,000 - 150,000 die as a result. The revolutionary filter design provides unique self-centering, ease of retrieval and low profile.

"The Crux filter was extremely easy to deploy. We are excited with the devices' ability to routinely self center in the vena cava and as result, we anticipate improved retrievability," Rosenthal stated. Atlanta's David Rosenthal is the Principal Investigator for Crux's pivotal IDE study, which is being conducted at 12 leading medical institutions in the United States.

Retrievable IVC filters were first introduced in the United States in 2002. They offer physicians the option to leave the device in on a permanent basis or to remove the filter via minimally invasive methods, once the patient is through the period when they are at risk for a PE. However current retrievable filters offer challenges to physicians. "Tilting of an IVC filter makes subsequent retrieval very challenging and can take up to several hours to accomplish," said Frank Arko, co-founder of Crux and Chief of Endovascular Surgery at University of Texas Southwestern. "I was amazed how easy it was to retrieve the Crux filter in our initial implants outside the United States. We were able to deploy or remove the filter in less than 5 minutes."

Annual sales of IVC filter in the United States are estimated to be $252MM in 2008 and growing between 8-10% annually. Filters are increasingly being used as a result of increased diagnosis of deep vein thrombosis and the protection that they afford in cases of trauma and orthopedic surgeries.

"Crux was able to design a device that is versatile and simple to use," stated Thomas Fogarty, M.D., cardiovascular surgeon and founder of Crux Biomedical. Mel Schatz, CEO of Crux states, "We have had very encouraging results from both our initial implants outside of the United States and feedback from our very experienced U.S. investigators. We are confident that we have developed an IVC filter that better meets the needs of implanting physicians."

Crux Biomedical, headquartered in Portola Valley, California, was founded in late 2004 by Dr. Thomas Fogarty and Dr. Frank Arko. The company is developing an implantable vascular device that offers significant improvement over existing IVC filters. The device has been successfully implanted in humans in international studies and has been granted approval by the FDA to initiate its pivotal IDE study.

For additional information contact Mel Schatz, Crux Biomedical, at (650) 851-2332, ext. 38, or mschatz@cruxbiomedical.com


'/>"/>
SOURCE Crux Biomedical, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Biomedical engineering conference invites manufacturers
2. Manufacturing partnership will move into biotech and biomedical spaces
3. Biomedical Alliance about more than stem cells
4. Doyle seeks $2.5M for biomedical alliance
5. Students will show off biomedical devices to professors and investors
6. Biomedical alliance marks first full year
7. UW Biomedical Engineering awarded $2.9 million research grant
8. Having two biomedical tech centers in Wisconsin will help the state
9. New biomedical institute aims to unite business and academia in SE Wisconsin
10. Wisconsin publicly traded biomedical companies report gains this quarter
11. Speaker announces business members of IT Task Force
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
(Date:10/9/2017)... ... October 09, 2017 , ... The Giving ... marijuana products targeting the needs of consumers who are incorporating medical marijuana into ... in Phoenix, Arizona. , As operators of two successful Valley dispensaries, The Giving ...
(Date:10/7/2017)... ... October 06, 2017 , ... Phase ... metagenome deconvolution product, featuring the first commercially available Hi-C kit. Researchers can ... Hi-C metagenome deconvolution using their own facilities, supplementing the company’s full-service ProxiMeta ...
(Date:10/6/2017)... (PRWEB) , ... October 06, 2017 , ... ... host a lunch discussion and webinar on INSIGhT, the first-ever adaptive clinical trial ... Investigator, Dana-Farber Cancer Institute. The event is free and open to the public, ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/30/2017)... 2017 The research team of The Hong ... fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery and ... speed and accuracy for use in identification, crime investigation, immigration control, ... ... A research team led ...
Breaking Biology News(10 mins):